Last reviewed · How we verify

Atlantic Health System — Portfolio Competitive Intelligence Brief

Atlantic Health System pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bupivacaine Hydrochloride and Lidocaine Bupivacaine Hydrochloride and Lidocaine marketed
Lidocaine gel 2% Lidocaine gel 2% marketed Local anesthetic Voltage-gated sodium channels Anesthesia/Pain Management
Intravesical antibiotic instillation Intravesical antibiotic instillation marketed Antibiotic instillation therapy Urology / Infectious Disease
Antibiotic oral suppressive therapy Antibiotic oral suppressive therapy marketed Antibiotic (suppressive therapy) Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams Maternity Hospital · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Aligarh Muslim University · 1 shared drug class
  4. Aultman Health Foundation · 1 shared drug class
  5. B.P. Koirala Institute of Health Sciences · 1 shared drug class
  6. Bagcilar Training and Research Hospital · 1 shared drug class
  7. Bayero University Kano, Nigeria · 1 shared drug class
  8. Abant Izzet Baysal University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Atlantic Health System:

Cite this brief

Drug Landscape (2026). Atlantic Health System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/atlantic-health-system. Accessed 2026-05-17.

Related